Focused On-demand Library for Cadherin-15

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P55291

UPID:

CAD15_HUMAN

Alternative names:

Cadherin-14; Muscle cadherin

Alternative UPACC:

P55291

Background:

Cadherin-15, also known as Muscle cadherin or Cadherin-14, plays a pivotal role in cell adhesion, being crucial for the formation and maintenance of tissues. As a calcium-dependent protein, it facilitates homophilic interactions that are essential for the sorting of diverse cell types. Its involvement in the myogenic program underscores its importance in muscle differentiation, highlighting its potential as a therapeutic target.

Therapeutic significance:

Cadherin-15's link to Intellectual developmental disorder, autosomal dominant 3, underscores its clinical relevance. Understanding the role of Cadherin-15 could open doors to potential therapeutic strategies, offering hope for interventions that could ameliorate or even prevent the manifestations of this disorder.